ReviewActa pharmacologica Sinica2014
Neuronal nicotinic acetylcholine receptors are important targets for alcohol reward and dependence.
Review in Acta pharmacologica Sinica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- The role of nicotinic receptors in alcohol consumption.Pharmacological research · 2023Pooled it
- Age-related differences in the effect of chronic alcohol on cognition and the brain: a systematic review.Translational psychiatry · 2022Pooled it
- Role of microRNAs in the pathophysiology of addiction.Wiley interdisciplinary reviews. RNA · 2021Pooled it
- Mecamylamine treatment for alcohol dependence: a randomized controlled trial.Addiction (Abingdon, England) · 2018Trial
- A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis.Journal of addiction medicineTrial
- Role of glial cells in neurotoxicological effects of alcohol.Advances in neurotoxicology · 2025Article
- FermentedInternational journal of molecular sciences · 2024Article
- MicroRNAs and Synaptic Plasticity: From Their Molecular Roles to Response to Therapy.Molecular neurobiology · 2022Review
- Ethanol reduces the minimum alveolar concentration of sevoflurane in rats.Scientific reports · 2022Article
- Anti-saccade as a Tool to Evaluate Neurocognitive Impairment in Alcohol Use Disorder.Frontiers in psychiatry · 2022Review
- Role of Sigma Receptors in Alcohol Addiction.Frontiers in pharmacology · 2019Review
- Nicotinic acetylcholine receptors (nAChRs) are expressed in Trpm5 positive taste receptor cells (TRCs).PloS one · 2018Article
- Bivariate genome-wide association analyses identified genetic pleiotropic effects for bone mineral density and alcohol drinking in Caucasians.Journal of bone and mineral metabolism · 2017Article
- Effect of single-nucleotide polymorphisms in ADH1B, ADH4, ADH1C, OPRM1, DRD2, BDNF, and ALDH2 genes on alcohol dependence in a Caucasian population.Pharmacology research & perspectives · 2017Article
- Behavioral Deficits Following Withdrawal from Chronic Ethanol Are Influenced by SLO Channel Function inGenetics · 2017Article
- Modeling gene regulation from paired expression and chromatin accessibility data.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- No evidence of a role of the β4 subunit of the nicotinic acetylcholine receptor in alcohol-related behaviors.BMC research notes · 2017Article
- Interactions between nicotine and drugs of abuse: a review of preclinical findings.The American journal of drug and alcohol abuse · 2017Review
- Recent Advances in Nicotinic Receptor Signaling in Alcohol Abuse and Alcoholism.Progress in molecular biology and translational science · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuronal nicotinic acetylcholine receptors are important targets for alcohol reward and dependence. Alcoholism is a serious public health problem and has been identified as the third major cause of preventable mortality in the world. Worldwide, about 2 billion people consume alcohol, with 76.3 million having diagnosable alcohol use disorders. Alcohol is currently responsible for the death of 4% of adults worldwide (about 2.5 million deaths each year), and this number will be significantly increased by 2020 unless effective action is taken. Alcohol is the most commonly abused substance by humans. Ethanol (EtOH) is the intoxicating agent in alcoholic drinks that can lead to abuse and dependence. Although it has been extensively studied, the mechanisms of alcohol reward and dependence are still poorly understood. The major reason is that, unlike other addictive drugs (eg, morphine, cocaine or nicotine) that have specific molecular targets, EtOH affects much wider neuronal functions. These functions include phospholipid membranes, various ion channels and receptors, synaptic and network functions, and intracellular signaling molecules. The major targets in the brain that mediate EtOH's effects remain unclear. This knowledge gap results in a therapeutic barrier in the treatment of alcoholism. Interestingly, alcohol and nicotine are often co-abused, which suggests that neuronal nicotinic acetylcholine receptors (nAChRs), the molecular targets for nicotine, may also contribute to alcohol's abusive properties. Here, we briefly summarize recent lines of evidence showing how EtOH modulates nAChRs in the mesolimbic pathway, which provides a perspective that nAChRs are important targets mediating alcohol abuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.